GlassScriptPhysician profile
William William Brand
NPI 1174511901
$2,385.05
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,358 · 2020: $582 · 2021: $397 · 2022: $48.89.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $814.02 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $349.51 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $332.33 | 2019-2021 | |
| Janssen Biotech, INC. | $209.69 | 2019-2021 | |
| Allergan, INC. | $144.40 | 2019-2020 | |
| Pfizer INC. | $116.97 | 2019 | |
| Shire North American Group INC | $90.68 | 2019 | |
| Daiichi Sankyo INC. | $88.09 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $51.46 | 2019 | |
| Alnylam Pharmaceuticals INC. | $37.96 | 2019 | |
| Merck Sharp & Dohme LLC | $35.98 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $29.75 | 2021 | |
| Covidien LP | $29.22 | 2019 | |
| Qol Medical, LLC | $27.34 | 2019-2020 | |
| Redhill Biopharma INC. | $16.44 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Concordia Pharmaceuticals INC. | $11.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Brand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.